FY4/23 3Q
Supplementary Materials

March 3, 2023

１．Consolidated Results■Year-on-Year(¥ million)

FY4/22 3Q
results

FY4/23 3Q
results

YoYchange

YoYchange(%)

Net sales

234,610

263,906+29,296+12.5

Gross profit

36,50039,692+3,192+8.7% of net sales

15.6

15.0

26,28628,006+1,720

+6.5

11.2

10.6

10,214

11,685+1,471

+14.4

4.4

4.4

10,80012,367+1,567

+14.5

4.6

4.7

6,231

6,628+397+6.4% of net sales

2.7

2.5

Earnings pershare(¥)

176.89188.70+11.81+6.7SG&A expenses% of net sales

Operating profit% of net sales

Ordinary profit% of net sales

Profit attributableto owners of parent

Figures in the table are rounded down

■Vs Plan(¥ million)

FY4/23 3Q
plan

FY4/23 3Q
results

Vs planchangeVs planchange(%)

Net sales

267,191

263,906(3,285)(1.2)

Gross profit

42,79339,692(3,101)(7.2)% of net sales

16.0

15.0

28,82628,006(820)

(2.8)

10.8

10.6

13,967

11,685(2,282)(16.3)

5.2

4.4

14,39012,367(2,023)(14.1)

5.4

4.7

7,703

6,628(1,075)(14.0)% of net sales

2.9

2.5

Earnings pershare(¥)

219.29188.70(30.59)(13.9)

SG&A expenses% of net sales

Operating profit% of net sales

Ordinary profit% of net sales

Profit attributableto owners of parent

Figures in the table are rounded down

-1-２. Segment Information（Dispensing Pharmacy Business）■Year-on-Year(¥ million)

FY4/22 3Q
results

FY4/23 3Q
results

YoYchange

YoYchange(%)

Net sales

209,793236,396+26,603+12.7

Gross profit

27,70329,448+1,745+6.3% of net sales

13.2

12.5

10,385

12,067+1,682+16.2

5.0

5.1

17,31817,380+62+0.4

8.3

7.4

17,78418,023+239

+1.3

8.5

7.6

SG&A expenses% of net sales

Operating profit% of net sales

Segment profit% of net sales

Figures in the table are rounded down
Segment profit is adjusted to ordinary profit shown on the consolidated statements of income■Vs Plan(¥ million)

FY4/23 3Q
plan

FY4/23 3Q
results

Vs planchange

Vs planchange(%)

Net sales

239,310236,396(2,914)(1.2)

Gross profit

32,45529,448(3,007)(9.3)% of net sales

13.6

12.5

11,80012,067

+267

+2.3

4.9

5.1

20,655

17,380(3,275)(15.9)

8.6

7.4

21,05518,023(3,032)(14.4)

8.8

7.6

SG&A expenses% of net sales

Operating profit% of net sales

Segment profit% of net sales

Figures in the table are rounded down
Segment profit is adjusted to ordinary profit shown on the consolidated statements of income-2-3. Segment Information（Cosmetic and Drug Store Business)■Year-on-Year(¥ million)

FY4/22 3Q
resultsFY4/23 3Qresults

YoYchange

YoYchange(%)

Net sales

15,286

18,836+3,550+23.2

Gross profit

5,170

7,102+1,932+37.4% of net sales

33.8

37.7

6,693

6,401(292)

(4.4)

43.8

34.0

(1,522)700+2,222--3.7(1,474)

737+2,211--

3.9

SG&A expenses% of net sales

Operating profit% of net sales

Segment profit% of net sales

Figures in the table are rounded down
Segment profit is adjusted to ordinary profit shown on the consolidated statements of income■Vs Plan(¥ million)

FY4/23 3Qplan

FY4/23 3Q
results

Vs planchange

Vs planchange(%)

Net sales

18,761

18,836+75+0.4

Gross profit

6,998

7,102+104+1.5% of net sales

37.3

37.7

6,933

6,401(532)

(7.7)

37.0

34.0

Operating profit

65

700+635+976.9% of net sales

0.3

3.7

Segment profit

65

737+672+1,033.8% of net sales

0.3

3.9

SG&A expenses% of net sales

Figures in the table are rounded down
Segment profit is adjusted to ordinary profit shown on the consolidated statements of income-2-4. Sales Verification■Dispensing Pharmacy Business (YoY）■Dispensing Pharmacy Business（Vs Plan）

Net sales

Net sales（%）

Average
Prescription
prescription
volume（%）
price

Average
Prescription
prescription
volumeprice

Same store (1,033)+2.0+1.7+0.2

Same store (1,033)

(2.0)

(0.7)

(1.3)

Store openings in theprevious year (49)+107.9+110.9(1.5)

Store openings in theprevious year (49)

+0.7

(4.0)

+4.8

+12.6

+12.3

+0.2

Total (1,210)

(1.2)

(1.6)

+0.3

Total (1,210)■Cosmetic and Drug Store Business（YoY）■Cosmetic and Drug Store Business (Vs Plan）

Net sales

Net sales（%）

Average
Number ofspending per
customers
customer（%）

Average
Number ofspending per
customers
customerSame store (60)

+14.9+14.9(0.0)

Same store (60)(0.1)

+2.1(2.2)

Store openings in theprevious year (12)+447.1+434.0+2.4

Store openings in theprevious year (12)(11.1)

(6.7)

(4.7)

+23.2

+22.8

+0.3

Total (76)

+0.4

+1.7

(1.3)

Total (76)-4-

5. Consolidated Balance Sheet■Assets(¥ million)

End-FY4/22 3Q

End-FY4/22End-FY4/23 3Q

ChangeCash on hand and in banks

55,641

59,72946,193(13,536)

Notes and accounts receivable

10,707

10,11011,269+1,159Inventories

16,972

14,79023,629+8,83994,837100,765

95,490(5,275)

17,984

17,512

20,591+3,079

8,745

8,581

10,584+2,00330,63430,63638,519+7,88338,17236,35247,539+11,187

Total intangible fixed assets

42,617

41,21953,110+11,891

Investments in securities

3,204

2,503

2,938+435

Deferred tax assets

4,614

5,319

6,118+799

Deposits and guarantees

22,89322,78524,823+2,038

Total investments and otherassets

39,904

39,84042,443+2,603

Total fixed assets

113,157

111,696

134,072+22,376

Total assets

207,994

212,461

229,562+17,101

Total current assets
Buildings and structures,net
Land
Total property,plant andequipment
Goodwill

Figures in the table are rounded down

Change:End-FY4/23 3Q compared with end-FY4/22
Capital expenditures(Purchases of property, plant and equipment and intangible fixed assets + Deposits and guarantees)
totaled ¥11,216million■Liabilities and Net Assets(¥ million)

End-FY4/22 3Q

End-FY4/22

Total liabilities and net assets

52,276
2,746
77,991
6,100
11,88989,881
21,89420,50077,800118,177
118,113207,994

Figures in the table are rounded down

Change:End-FY4/23 3Q compared with end-FY4/22

Accounts payable
Short-term debt
Total current liabilities
Long-term debt
Total long-term liabilities
Total liabilities
Common stock
Capital surplus
Retained earnings
Total shareholders’ equity
Total net assets

50,7562,643
81,805
5,815
11,64593,45021,89420,50078,661
119,038
119,010
212,461End-FY4/23 3Q-5-60,972
4,036
92,823
5,816
12,995
105,819
21,89420,504
83,357
123,756
123,743
229,562

Change+10,216+1,393+11,018+1+1,350+12,369+4+4,696+4,718+4,733+17,101

6. FY4/23 Plan (Consolidated)(¥ million)

FY4/22
results

FY4/23
initial plan

FY4/23
revised plan

YoY
Vs initial planchange(%) change (%)

Net sales

316,247

363,000

358,000+13.2(1.4)

Gross profit

49,97158,72054,870+9.8(6.6)% of net sales

15.8

16.2

15.3

34,832

38,72037,690+8.2(2.7)

11.0

10.7

10.5

15,13920,00017,180+13.5(14.1)

4.8

5.5

4.8

16,041

20,50018,030+12.4(12.0)

5.1

5.6

5.0

7,092

11,0009,000+26.9(18.2)% of net sales

2.2

3.0

2.5

Earnings pershare(¥)

201.47313.15256.20+27.2(18.2)

Annual dividend (¥)

55.00

60.00

60.00

+9.1

0

SG&A expenses% of net sales

Operating profit% of net sales

Ordinary profit% of net sales

Profit attributableto owners of parent

Figures in the table are rounded down
YoY Change:FY4/23revised plan compared with FY4/22results-6-7. Transition of Store Openings■Number of Store Openings in Dispensing Pharmacy Business
FY4/15 FY4/16 FY4/17 FY4/18 FY4/19 FY4/20 FY4/21 FY4/22

FY4/233QOrganic

403227252314152518

M&A119110

182

11134

61424112Total

754881

1,066

1,029

1,132

1,088

1,065

1,099

1,210

■Number of Store Openings in Cosmetic and Drug Store Business
FY4/15 FY4/16 FY4/17 FY4/18 FY4/19 FY4/20 FY4/21 FY4/22FY4/233Q

Organic

359471511124Total

56

5252

4854

63

697876Inquiries related to this presentation should be addressed toAIN HOLDINGS INC.
Corporate Planning Division
TEL(81)11-814-0010
FAX(81)11-814-5550
https://www.ainj.co.jp/
This document may not be reproduced or distributed to any third party without
prior approval of AIN HOLDINGS INC. This document has been prepared for
information purpose only and does not form part of a solicitation to sell orpurchase any securities. Information contained herein may be changed orrevised without prior notice. This document may contain forecasting statements
as to future results of operations. No forecast statement can be guaranteed andactual results of operations may differ from those projected.

-7-